fbpx ABOUT CONTINUOUS GLUCOSE MONITORING | Medtronic Diabetes Israel

ABOUT CONTINUOUS GLUCOSE MONITORING

Continuous Glucose Monitoring (CGM) provides the complete picture by revealing lows and highs that HbA1C and fingerstick testing alone cannot always identify.

PAGE HIGHLIGHTS

  • What continuous glucose monitoring is and how it can help you

Share

Glucose monitoring data graph

If you are using the CGM features of your pump, you can see your glucose levels 24 hours a day. The pump, when combined with the Guardian 2 Link transmitter and the New Generation Enlite glucose sensor, wirelessly transmits readings to your MiniMed 640G. The readings are updated every five minutes and appear on the screen in colour. These regular updates can give you a clear understanding of how your glucose is behaving and reduce your dependence on a blood glucose finger testing*. You only need to change your glucose sensor every 6 days.

THE EVIDENCE

The advantages of CGM over traditional fingersticks and HbA1c testing are well-documented. Research has shown that:

  • CGM identifies four times as many serious glucose excursions as self-monitoring of blood glucose (SMBG)1
  • CGM can significantly reduce HbA1c and has been shown to reduce  HbA1c levels by up to 1% when compared with glucose finger blood sample testing alone 2
  • CGM is proven to be accurate in numerous published studies enabling you to make therapy adjustments based on reliable data

HOW CAN IT BENEFIT ME?

The anecdotal and real-life stories from patients using CGM are overwhelming and includes:

  • Parents who can relax and no longer feel that they have to check on their child through the night
  • Sports enthusiasts and students who can concentrate on competing or taking their exams without worrying
  • People with busy work lives who can be as busy as they like and get on with their day-to-day activities with less anxiety
  • Women who are pregnant or are thinking about becoming pregnant

SELF-FUNDING MAY BE AN OPTION

We would like everyone that could benefit from CGM to have the opportunity to use it.

Entitlement for funding according to the Health services:

  1. Children up to age 18 (who experience hypoglycemia events)*
  2. Pregnant women or in preparation for pregnancy (type 1 diabetes).
  3. Adults (18 years old and older) who experienced two documented hypoglycemia events requiring hospitalization and / or evacuation by an ambulance.

For those patients who experience challenges with regard to CGM funding, self-funding an option. Your MiniMed™ 640G pump is 'CGM-ready', so you may decide to fund CGM when you first receive your pump, or you can start any time at a later date. There are many options available.

All you need to get started is a CGM starter kit with Guardian 2 Link transmitter, Guardian™ 2 Link Charger, 5 New Generation Enlite sensors and Serter.  Just call our Customer Services Team to place an order or to ask for pricing information on: 09-9724489

*According to the guidelines published in the health agreement.

You will need to wear a small glucose sensor that sits under the skin for up to 6 days at a time. Just like an infusion set cannula, the sensor is easily inserted using an automatic device provided with the system. 85% Of patients agreed that insertion with New Generation Enlite was pain free**. The sensor attaches to a small lightweight transmitter** that sends glucose sensor data wirelessly to your insulin pump or a CGM stand-alone monitor through advanced radio frequency (RF) wireless technology.

The insulin pump or CGM monitor displays the glucose data On Screen and plots a Trend Line of the data so that you can see exactly what your glucose trends are and what may be affecting them.

As well as seeing the on-screen display, you can set Alerts on the insulin pump that will sound or vibrate to warn you when you are likely to reach, are reaching or have reached your glucose target limits. Having this information can help you to avoid hypo- or hyperglycaemic excursions, remain within your target glucose levels and help to reduce your HbA1C and achieve better control.

References

  • 1Pitzer KR, Desai S, Dunn T, et al. Detection of hypoglycemia with the GlucoWatch biographer. Diabetes Care. 2001;24(5):881-885.
  • 2Kaufman FR, et al. Diabetes Care. 2001;24(12):2030-2034
  • 3Raccah D, Sulmont V, Resnik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250
  • * This data is intended to supplement, not replace, blood glucose information obtained using standard home blood glucose monitoring devices. Fingersticks are required when adjusting insulin delivery and for calibrating the glucose sensor. Values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a meter blood glucose measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose meter and not on CGM system values.
  • ** Internal date on file; Medtronic MiniMed, Inc

Guardian™ 2 Link transmitter is only compatible with MiniMed 640G insulin pump

MiniLink™ transmitter is compatible with MiniMed™ Paradigm® Veo™ system and Guardian REAL-Time CGM system

 

The content and all information provided on this website is for your informational use only and is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner. The patient stories provided are experiences specific to a particular patient. Responses to a treatment may vary from patient to patient. Always talk with your physician about diagnosis and treatment information and ensure that you understand and carefully follow that information.

© 2016 Medtronic International Trading Sarl™. All Rights Reserved. No part of this website may be reproduced or utilized in any form or by any means without permission from Medtronic International Trading Sarl. MiniMed, Bolus Wizard, SMARTGUARD, Guardian, Enlite and CareLink are trademarks of Medtronic, Inc. and its subsidiaries. CONTOUR is a trademark of Bayer Healthcare LLC.